Chris Dockendorff
Chief Scientific Officer & Chief Executive Officer Function Therapeutics
Chris is the CSO & CEO of Function Therapeutics, a young preclinical firm developing anti-inflammatory and anti-thrombotic compounds with a focus on allosteric GPCR modulators. He previously served on the faculty of Marquette University and was a research scientist at the Broad Institute and NPS Pharmaceuticals. Originally trained as an organic chemist, Chris’ diverse research has included synthetic methods, medicinal chemistry, and GPCR pharmacology.
Seminars
Wednesday 29th April 2026
Roundtable Discussion: Assessing the Pharmacological Impact of GPCR Biased Signaling, Endosomal Pathways & Oligomerization
9:30 am
- What are the current best practices for measuring GPCR signaling bias in vitro, and what limitations do they have for in vivo and clinical translation?
- What are the pros and cons of therapeutic targeting of oligomeric GPCRs? Are there targets that you think are especially promising for successful clinical translation?
- Are there current pharmacological tools for targeting endosomal GPCRs that may have broad translational potential? If not, why not?
